Solventum Corp (SOLV) Upgraded to a ‘Buy’ at Argus Research

Solventum Corporation (NYSE:SOLV) is one of the 15 successful spin-off companies. On July 1, analysts at Argus Research upgraded the company to a ‘Buy’ from a Hold.’ The analysts also reiterated a $90 price target on the stock. The adjustment comes amid growing confidence that the company is enjoying robust growth.

Solventum Corp (SOLV) Upgraded to a ‘Buy’ at Argus Research

A healthcare professional in a meeting with a patient discussing care options using digital technology.

The upgrade underscores Argus Research’s confidence in Solventum Corp’s ability to execute its long-range plan. The firm expects the company to achieve its margin and revenue targets. In addition, the research firm cited the company’s higher-margin business as one of the reasons behind the upgrade.

Consequently, the research firm has raised its adjusted earnings estimate for the company’s 2026 fiscal year from $5.95 to $5.98 per share. In the first quarter of 2025, Solventum achieved top-line results with robust revenue of $8.3 billion and a solid gross margin of 54.9%.

Solventum Corporation is a global healthcare company that was formed following a spin-off from the 3M healthcare business. It develops, manufactures, and commercializes solutions that leverage material science, data science, and digital capabilities to improve healthcare.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

This article is originally published at Insider Monkey.